SYNACTHEN DEPOT ( DrugBank: - )

3 diseases

ID	Disease name (Link within this page)	Number of trials
83	Addison disease	2
145	West syndrome	2
222	Primary nephrotic syndrome	1

83. Addison disease

Clinical trials : 20 / Drugs : 43 - (DrugBank : 13) / Drug target genes : 6 - Drug target pathways : 18

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-001682-33-GB (EUCTR)	06/09/2012	15/06/2012	Rescue of Addison’s disease 2	Combined Immunotherapy and Trophic Adrenocortical Stimulation in New Onset Autoimmune Addison’s Disease - Rescue of Addison’s disease 2 (RADS2)	Autoimmune Addison's disease: autoimmune primary adrenal insufficiency MedDRA version: 16.1;Level: PT;Classification code 10052381;Term: Primary adrenal insufficiency;System Organ Class: 10014698 - Endocrine disorders MedDRA version: 16.1;Level: LLT;Classification code 10001335;Term: Adrenal cortex insufficiency;Classification code 10001342;Term: Adrenal cortical hypofunction;System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: Mabthera infusion Product Name: Mabthera Infusion Product Code: Rituximab Trade Name: Solu-Medrone Product Name: Solu-Medrone Product Code: Methylprednisolone Trade Name: Synacthen Depot Product Name: Synacthen Depot Product Code: Tetracosactide acetate	Newcastle upon Tyne Hospitals NHS Foundation Trust	NULL	Not Recruiting			Female: yes Male: yes	30	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom
2	EUCTR2009-018074-56-GB (EUCTR)	05/05/2010	18/03/2010	Revival of autochthonous adrenocortical stem cells in autoimmune Addison’s disease (RoSA) - Revival of Stem cells in Addison's disease (RoSA)	Revival of autochthonous adrenocortical stem cells in autoimmune Addison’s disease (RoSA) - Revival of Stem cells in Addison's disease (RoSA)	Autoimmune Addison's disease MedDRA version: 9.1;Level: HLT;Classification code 10001343;Term: Adrenal cortical hypofunction	Trade Name: Synacthen Depot Product Name: Synacthen Depot	Newcastle upon Tyne Hospitals NHS Foundation Trust	NULL	Not Recruiting			Female: yes Male: yes	12		United Kingdom

145. West syndrome

Clinical trials : 43 / Drugs : 54 - (DrugBank : 15) / Drug target genes : 27 - Drug target pathways : 24

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2006-000788-27-DE (EUCTR)	23/09/2010	11/06/2010	International Collaborative Study of a type of epilepsy called Infantile Spasms	International Collaborative Infantile Spasms Study (ICISS) - ICISS	Infantile spasms are a rare severe form of epilepsy affecting approx 1 in 2,250 infants, usually under the age of 1 year. Affected infants have a very abnormal EEG and a poor prognosis for subsequent epilepsy and neuro-development. There is a high risk of underlying neurological disease that independently causes delayed development and other seizure disorders. There is a high risk of a poor outcome even when there is no other detectable underlying neurological disorder.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SABRIL INN or Proposed INN: Vigabatrin Trade Name: Synacthen Depot INN or Proposed INN: Tetracosactide Acetate Trade Name: Decortin H INN or Proposed INN: Prednisolone	Royal United Hospital Bath NHS Trust	NULL	Not Recruiting			Female: yes Male: yes	410	Phase 4	Australia;Germany;United Kingdom;Switzerland;New Zealand
2	EUCTR2006-000788-27-GB (EUCTR)	20/04/2006	06/03/2006	International Collaborative Infantile Spasms Study (ICISS) - ICISS	International Collaborative Infantile Spasms Study (ICISS) - ICISS	Infantile spasms are a rare severe form of epilepsy affecting approx 1 in 2,250 infants, usually under the age of 1 year. Affected infants have a very abnormal EEG and a poor prognosis for subsequent epilepsy and neuro-development. There is a high risk of underlying neurological disease that independently causes delayed development and other seizure disorders. There is a high risk of a poor outcome even when there is no other detectable underlying neurological disorder.	Trade Name: SABRIL SACHETS INN or Proposed INN: Vigabatrin Trade Name: SYNACTHEN DEPOT INN or Proposed INN: Tetracosactide Acetate Trade Name: SOLUBLE PREDNISOLONE TABLETS INN or Proposed INN: Prednisolone	Royal United Hospital Bath NHS Trust	NULL	Not Recruiting			Female: yes Male: yes	410	Phase 4	Germany;United Kingdom

222. Primary nephrotic syndrome

Clinical trials : 285 / Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2008-001647-19-NL (EUCTR)	22/05/2008	04/06/2008	Treatment with synthetic adrenocoticotropic hormone (ACTH) in patients with membranous nephropathy and high risk for renal failure. A pilot study. - ACTHiMeN	Treatment with synthetic adrenocoticotropic hormone (ACTH) in patients with membranous nephropathy and high risk for renal failure. A pilot study. - ACTHiMeN	Membranous nephropathy MedDRA version: 9.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy	Trade Name: Synacthen Depot 1mg	Radboud University Nijmegen Medical Center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands